List view / Grid view
26 April 2016 | By Victoria White, Drug Target Review
In an exclusive interview, Trevor Perrior, Research Director at Domainex, discusses the cell death regulatory protein FLIP and the potential of FLIP inhibitors as a treatment for NSCLC...
25 April 2016 | By Victoria White, Drug Target Review
We've created an infographic on the threat of antibiotic resistance, highlighting some of the recommendations made by the Review on Antimicrobial Resistance to date...
22 April 2016 | By Snehal Chougule, Allied Market Research
Here, Snehal Chougule discusses Trajan's recent investment in automation solution company, LEAP Technologies Inc...
12 April 2016 | By Caroline Richards, Editor, Drug Target Review
Here, Caroline Richards, Editor of Drug Target Review, discusses the publication and the opportunities available to authors...
31 March 2016 | By Victoria White, Drug Target Review
We asked readers of if they agreed with BIA that the UK pharmaceutical industries are stronger in the EU. The results of that poll are now in...
23 March 2016 | By Dr John Maher, Principal Investigator, National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Guy’s and St Thomas’ and Kings College London
Here, Dr John Maher of the NIHR BRC at Guy's and St Thomas' and Kings College London discusses CAR T-cell therapy and the exciting frontier the technique has opened up in the battle against cancer...
17 March 2016 | By Drug Target Review
Included in this issue: Microfluidics, Protein Expression, Drug Targets, Biomarkers, Oncology, Assays, Antibodies, and much more...
In this Antibodies In-depth Focus: Antibody fragment technology and avian IgY antibodies: a powerful combination; plus the challenges with antibody-based targeting of VEGF...
In this Assays In-Depth Focus: "Finding a cure for neglected tropical diseases with cell-based assays", plus "The relevance of homogeneous radiometric assays in modern drug discovery"...
Long term success for pharmaceutical businesses depends upon harnessing the best tools available to bring safe and effective medicines to market at a competitive price, and to be truly successful, for such drugs to be first in class.
17 March 2016 | By Drug Target Review
In this Drug Targets In-Depth Focus: "The alarming increase in antibioticresistant bacteria", plus "Computational methods for drug repositioning"; and "An overview of Alzheimer’s disease drug targets"...
Caroline Richards, Editor of Drug Target Review, asks Amrik Basran, Chief Scientific Officer at Avacta Life Sciences, to provide his views on Affimer® technology...
Microfluidic technology has great potential for complementing and, in some instances, replacing the use of animal models in the testing of medicines and in developing personalised treatments for cancer patients.
Biopharmaceuticals are highly complex protein drugs such as antibodies, cytokines and peptide hormones, which are used for a variety of indication areas, including immunology, neurology, metabolic diseases and cancer. These modern protein drugs may hinder progression of a disease, ease symptoms or assure – in the case of chronic diseases…
Non-alcoholic fatty liver disease (NAFLD), a consequence of sedentary life styles and high fat diets, has an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms within genes such as PNPLA3, TM6SF2, APOC3, NCAN and PPP1R3B correlate…
